Race Oncology Ltd (FRA:FN3)
€ 0.785 -0.04 (-4.85%) Market Cap: 142.35 Mil Enterprise Value: 131.76 Mil PE Ratio: 0 PB Ratio: 12.31 GF Score: 42/100

Race Oncology Ltd at Vertical Events Gold Coast Investment Showcase Transcript

Jun 22, 2022 / 12:15AM GMT
Daniel Tillett
Race Oncology Ltd - Chief Scientific Officer & Executive Director

Thank you. So, after sitting through six resource presentations, we get to take a look at a biotech presentation, so I'll jump over the disclaimer, quick overview of the company. It had a interesting run over the last two years, right up from I joined in 2019 at the time when the share price was below $0.05. And it's run up to about $4, set at $3 for a while, and then got smashed along with all the other biotechs over the last six months or so, great opportunity to get into the biotech space, if you're not in that.

We only have 160 million shares on issue, not too many options. We have around almost 10,000 shareholders -- 9,500. We have a share price market cap around quarter of a billion dollars, which is very important for biotech, compared to resource companies, which you can run on a smell of an oily rag. Biotech is very expensive. We've got $35.7 million of cash in the bank. And We have an enterprise value of around $230 million.

I'm the largest shareholder of the company. I came in as an investor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot